Celgene wins PTCL approval in US for Istodax
This article was originally published in Scrip
Executive Summary
The US FDA granted accelerated approval for Celgene to market its histone deacetylase inhibitor Istodax (romidepsin) as a treatment for peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.